{"entity":{"id":"nct05393713","kind":"trial","name":"Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study","aka":[],"tldr":"A phase 1 trial of IMC-001 run by Mayo Clinic, terminated.","summary":"Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study is a phase 1 interventional study registered as NCT05393713 by Mayo Clinic, with 3 participants enrolled, started 2022-10-17. Conditions recorded: Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma and Recurrent Metastatic Melanoma. Interventions recorded: Anti-PD-L1 Monoclonal Antibody IMC-001 and Punch Biopsy.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05393713","url":"https://clinicaltrials.gov/study/NCT05393713"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["imc-001"],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05393713","phase":"1","setting":"Phase 1 Study of the Administration of STI-3031 (Anti-PDL1) Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE in Patients With In-Transit Melanoma (Sofusa-2)","sponsor":"Mayo Clinic","enrolled":3,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05393713/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"imc-001","kind":"drug","name":"IMC-001","route":"/drugs/imc-001/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}]}}